Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.
2023
Improved RFS in Resected Melanoma with mRNA Vaccine/Pembrolizumab
Pembrolizumab and mRNA-4157 demonstrated improvements in subgroups of resected melanoma, including those with BRAF-mutated tumors, in the phase 2 KEYNOTE-942 trial.
Survival Benefit Observed With Adjuvant Cemiplimab in Skin Cancer Subtype
Results presented at 2023 ESMO showed a prolonged survival benefit in patients receiving adjuvant cemiplimab for stage II-IV cutaneous squamous cell carcinoma.
Adoptive cell therapy using TILs shows clinically meaningful and durable efficacy in advanced mucosal melanoma
Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma